TABLE 1.
Human HIV-1 clinical efficacy (2B and 3) trials that included Env immunizations given as protein or expressed from vector or both
| Study (reference) | Immunogensa | Vaccine efficacyb | Proposed CoPc |
|---|---|---|---|
| VAX004 (50, 116) | AIDSVAX, B/B gp120 × 7, alum adjuvant | NS | |
| VAX003 (117) | AIDSVAX, B/E gp120 × 7, alum adjuvant | NS | |
| RV144-RV152 (2, 51, 55, 59) | Prime: ALVAC-HIV (vCP1521) × 4; boost: AIDSVAX gp120 B/E (MN/A244) × 2,d in alum adjuvant | 31% at 3.5 yr by MITT analysis | High V1V2 Ab reactivity in plasma, low Env-specific IgA in plasma |
| HVTN 505 (62) | Prime: DNA gag, pol, nef, env A/B/C × 3; boost: rAd5 gag-pol B, env A/B/C × 1 | NS | |
| HVTN 702 (3) | Prime: ALVAC-HIV (vCP2438) × 6; boost: bivalent gp120 C (TV1/1086) × 4,d in MF59 adjuvant | NS | |
| HVTN 705 /HPX2008 (4, 41) | Prime: Ad26 mosaic HIV (gag, pol, env) × 4; boost: gp140 C × 2, in alum adjuvant | NS |
a
Single capital letters with or without slashes denote clade of viral gene or protein, e.g., C, B/E, A/B/C.
b
NS, nonsignificant VE. MITT, modified intention to treat; protection was not significant in the other protocols with intention to treat and per protocol.
c
No tier-2-neutralizing responses, i.e., no bNAb responses were detected.
d
Protein boosts were given simultaneously with the last two or four vector immunizations.